Rituximab With High-dose Sequential Chemo Fails to Improve DLBCL Outcomes

Share this content:
Rituximab With High-dose Sequential Chemo Fails to Improve DLBCL Outcomes
Rituximab With High-dose Sequential Chemo Fails to Improve DLBCL Outcomes

Frontline treatment with rituximab plus high-dose sequential chemotherapy with autologous hematopoietic stem cell transplantation (HSCT) failed to improve progression-free or overall survival compared with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) chemoimmunotherapy in patients with diffuse large B-cell lymphoma (DLBCL), a study published in the Journal of Clinical Oncology has shown.1

Because the benefit of high-dose chemotherapy with autologous HSCT as first-line therapy in patients with DLBCL remains controversial, researchers sought to compare the efficacy and safety of R-CHOP with rituximab plus high-dose sequential chemotherapy and autologous HSCT.

For the phase 3 study (ClinicalTrials.gov Identifier: NCT00355199), investigators enrolled 246 high-risk patients with a high-intermediate or high International Prognostic Index score. Participants were randomly assigned to receive R-CHOP or rituximab with high-dose sequential chemotherapy.

Results showed that clinical response rates were similar between treatment arms, with 78% of patients treated with R-CHOP achieving a complete response vs 76% of those given high-dose sequential chemotherapy and rituximab.

At a median follow-up of 5 years, investigators found that 3-year event-free survival was 62% and 65% with R-CHOP and sequential chemotherapy with rituximab, respectively (P =.83).

There were also no significant differences in progression-free survival (P =.12) or overall survival (P =.64) between the 2 treatment arms.

However, rituximab plus high-dose sequential chemotherapy was associated with significantly higher hematologic toxicity (P <.001) and a greater incidence of infectious complications (P <.001) than the R-CHOP arm.


1. Cortelazzo S, Tarella C, Gianni AM, et al. Randomized trial comparing R-CHOP versus high-dose sequential chemotherapy in high-risk patients with diffuse large b-cell lymphomas. J Clin Oncol. 2016 Oct 3. doi: 10.1200/JCO.2016.67.2980. [Epub ahead of print]

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs